Abbott recalls beetle-laced baby formula; Was Elan's governance report objective?;

 @FiercePharma: Layoffs return with Abbott's 3,000 job cuts. Article | Follow @FiercePharma

> Abbott Laboratories is voluntarily recalling millions of containers of its top-selling Similac powdered infant formulas after beetles were found in the products and in the Michigan plant where they are made. Abbott release | Report

> New questions have arisen about the independence of a report prepared by a U.S. law firm that cleared Irish drugmaker Elan of any breaches of corporate governance or other wrongdoing. Report

> Janssen U.K. plans to launch a wide-ranging social media campaign to raise awareness of the chronic skin condition psoriasis. Report

> The European Commission has cleared Deutsche Bank's planned acquisition of Icelandic generics maker Actavis. Report

> Biovail and Valeant Pharmaceuticals expect their $3.2-billion merger will be completed by September 28, earlier than many on the Street anticipated. Report

> Bayer says it is launching Betaferon for the treatment of relapsing-remitting forms of multiple sclerosis in China. Report

> Even before Watson Pharmaceuticals' new emergency contraceptive ella arrives on U.S. pharmacy shelves, opponents are campaigning to persuade pharmacists not to fill prescriptions for the drug. Report

> Goldman Sachs analyst Mark Beards cut his rating on Novartis (NVS) to "Neutral" from "Buy," listing the company among the Big Pharma outfits most exposed to a looming disaster at the hands of generic drugs. Report

Biotech News

@FierceBiotech: Novartis wins landmark approval for oral MS drug. Article | Follow @FierceBiotech

 @JohnCFierce: Lundbeck is cutting its R&D staff while shifting to more collaborations on brain diseases. Article | Follow @JohnCFierce

> BioMed raising cash is it wheels and deals on biotech campuses. News

> Third Rock leads $30M round for antibody upstart. Article

> Reata scores $450M in quick cash from Abbott pact. News

Vaccines News

> Cervical cancer vax ready to enter human trials. News

> IDT expands vax manufacturing and workforce. Story

> Plant-based H1N1 vax starts clinical trial. Report

> Breast cancer vax could protect women from their 40s. Article

Manufacturing News

> Newly posted warning cites repeat violation. Story

> Pfizer, Sproxil aid in safe drug access programs. Article

> Report: DEA wants controls on propofol. News

> Google sues online merchants of drug fakes. Story

And Finally... The raised risk of cancer in people using insulin decreases over time, a large study showed, announced Novo Nordisk, the world's biggest maker of insulin. Report

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.